Notably, recent studies suggest that increased activation of the PI3K-AKT pathway in brain metastases compared to patient-matched primary tumors and extracranial metastases is observed in many different tumor types, further supporting the rationale for therapeutic development and clinical trials in this area.17,57. The gene discussed is PIK3CA; the disease is neoplasm.